Multimodality Imaging of Prostate Cancer

Overview

Journal J Nucl Med

Specialty Nuclear Medicine

Date 2019 Sep 5

PMID 31481573

Citations 31

Authors

Soleen Ghafoor

Irene A Burger

Alberto H Vargas

Affiliations

Soon will be listed here.

Abstract

Prostate cancer is a very heterogeneous disease, and contemporary management is focused on identification and treatment of the prognostically adverse high-risk tumors while minimizing overtreatment of indolent, low-risk tumors. In recent years, imaging has gained increasing importance in the detection, staging, posttreatment assessment, and detection of recurrence of prostate cancer. Several imaging modalities including conventional and functional methods are used in different clinical scenarios with their very own advantages and limitations. This continuing medical education article provides an overview of available imaging modalities currently in use for prostate cancer followed by a more specific section on the value of these different imaging modalities in distinct clinical scenarios, ranging from initial diagnosis to advanced, metastatic castration-resistant prostate cancer. In addition to established imaging indications, we will highlight some potential future applications of contemporary imaging modalities in prostate cancer.

Citing Articles

Three-dimensional spatial localization and volume estimation of prostate tumors using F-PSMA-1007 PET/CT versus multiparametric MRI.

Huang G, Albers P, Mookerji N, Pfanner T, Hui A, Mittal R Eur J Nucl Med Mol Imaging. 2024; .

PMID: 39725694 DOI: 10.1007/s00259-024-07021-0.

Trend in incidence and clinicopathological characteristics of prostate cancer in Northern Tanzania: analysis from a population based cancer registry data 2015-2021.

Ngowi B, Mremi A, Mbwambo O, Seventh F, Kalonge S, Nkya C BMC Cancer. 2024; 24(1):1424.

PMID: 39563287 PMC: 11575071. DOI: 10.1186/s12885-024-13194-6.

MR Molecular Imaging of Extradomain-B Fibronectin for Assessing Progression and Therapy Resistance of Prostate Cancer.

Vaidya A, Shankardass A, Buford M, Hall R, Qiao P, Wang H Chem Biomed Imaging. 2024; 2(8):560-568.

PMID: 39211789 PMC: 11351422. DOI: 10.1021/cbmi.4c00002.

Radiology of fibrosis part III: genitourinary system.

Tarchi S, Salvatore M, Lichtenstein P, Sekar T, Capaccione K, Luk L J Transl Med. 2024; 22(1):616.

PMID: 38961396 PMC: 11223291. DOI: 10.1186/s12967-024-05333-1.

Unveiling the best predictive models for early‑onset metastatic cancer: Insights and innovations (Review).

Yu L, Huang Z, Xiao Z, Tang X, Zeng Z, Tang X Oncol Rep. 2024; 51(4).

PMID: 38456540 PMC: 10940877. DOI: 10.3892/or.2024.8719.

References

Grubmuller B, Baltzer P, Hartenbach S, DAndrea D, Helbich T, Haug A . PSMA Ligand PET/MRI for Primary Prostate Cancer: Staging Performance and Clinical Impact. Clin Cancer Res. 2018; 24(24):6300-6307. DOI: 10.1158/1078-0432.CCR-18-0768. View

Yadav S, Stockert J, Hackert V, Yadav K, Tewari A . Intratumor heterogeneity in prostate cancer. Urol Oncol. 2018; 36(8):349-360. DOI: 10.1016/j.urolonc.2018.05.008. View

Padhani A, Lecouvet F, Tunariu N, Koh D, De Keyzer F, Collins D . Rationale for Modernising Imaging in Advanced Prostate Cancer. Eur Urol Focus. 2017; 3(2-3):223-239. DOI: 10.1016/j.euf.2016.06.018. View

Evangelista L, Guttilla A, Zattoni F, Muzzio P, Zattoni F . Utility of choline positron emission tomography/computed tomography for lymph node involvement identification in intermediate- to high-risk prostate cancer: a systematic literature review and meta-analysis. Eur Urol. 2012; 63(6):1040-8. DOI: 10.1016/j.eururo.2012.09.039. View

Zacho H, Nielsen J, Afshar-Oromieh A, Haberkorn U, deSouza N, De Paepe K . Prospective comparison of Ga-PSMA PET/CT, F-sodium fluoride PET/CT and diffusion weighted-MRI at for the detection of bone metastases in biochemically recurrent prostate cancer. Eur J Nucl Med Mol Imaging. 2018; 45(11):1884-1897. DOI: 10.1007/s00259-018-4058-4. View

Wu L, Xu J, Gu H, Hua J, Zhu J, Chen J . Role of magnetic resonance imaging in the detection of local prostate cancer recurrence after external beam radiotherapy and radical prostatectomy. Clin Oncol (R Coll Radiol). 2013; 25(4):252-64. DOI: 10.1016/j.clon.2012.11.010. View

Eggener S, Scardino P, Walsh P, Han M, Partin A, Trock B . Predicting 15-year prostate cancer specific mortality after radical prostatectomy. J Urol. 2011; 185(3):869-75. PMC: 4058776. DOI: 10.1016/j.juro.2010.10.057. View

Jilg C, Drendel V, Rischke H, Beck T, Reichel K, Kronig M . Detection Rate of F-Choline PET/CT and Ga-PSMA-HBED-CC PET/CT for Prostate Cancer Lymph Node Metastases with Direct Link from PET to Histopathology: Dependence on the Size of Tumor Deposits in Lymph Nodes. J Nucl Med. 2019; 60(7):971-977. PMC: 6604697. DOI: 10.2967/jnumed.118.220541. View

Hofman M, Murphy D, Williams S, Nzenza T, Herschtal A, De Abreu Lourenco R . A prospective randomized multicentre study of the impact of gallium-68 prostate-specific membrane antigen (PSMA) PET/CT imaging for staging high-risk prostate cancer prior to curative-intent surgery or radiotherapy (proPSMA study): clinical trial.... BJU Int. 2018; 122(5):783-793. DOI: 10.1111/bju.14374. View

10.

Borofsky S, George A, Gaur S, Bernardo M, Greer M, Mertan F . What Are We Missing? False-Negative Cancers at Multiparametric MR Imaging of the Prostate. Radiology. 2017; 286(1):186-195. PMC: 5749595. DOI: 10.1148/radiol.2017152877. View

11.

Torabi M, Aquino S, Harisinghani M . Current concepts in lymph node imaging. J Nucl Med. 2004; 45(9):1509-18. View

12.

Ceder Y, Bjartell A, Culig Z, Rubin M, Tomlins S, Visakorpi T . The Molecular Evolution of Castration-resistant Prostate Cancer. Eur Urol Focus. 2017; 2(5):506-513. DOI: 10.1016/j.euf.2016.11.012. View

13.

Park S, Zacharias C, Harrison C, Fan R, Kunder C, Hatami N . Gallium 68 PSMA-11 PET/MR Imaging in Patients with Intermediate- or High-Risk Prostate Cancer. Radiology. 2018; 288(2):495-505. DOI: 10.1148/radiol.2018172232. View

14.

Donohoe K, Cohen E, Giammarile F, Grady E, Greenspan B, Henkin R . Appropriate Use Criteria for Bone Scintigraphy in Prostate and Breast Cancer: Summary and Excerpts. J Nucl Med. 2017; 58(4):14N-17N. View

15.

Pandit-Taskar N, Veach D, Fox J, Scher H, Morris M, Larson S . Evaluation of Castration-Resistant Prostate Cancer with Androgen Receptor-Axis Imaging. J Nucl Med. 2016; 57(Suppl 3):73S-78S. DOI: 10.2967/jnumed.115.170134. View

16.

Padhani A, Lecouvet F, Tunariu N, Koh D, De Keyzer F, Collins D . METastasis Reporting and Data System for Prostate Cancer: Practical Guidelines for Acquisition, Interpretation, and Reporting of Whole-body Magnetic Resonance Imaging-based Evaluations of Multiorgan Involvement in Advanced Prostate Cancer. Eur Urol. 2016; 71(1):81-92. PMC: 5176005. DOI: 10.1016/j.eururo.2016.05.033. View

17.

Barchetti F, Stagnitti A, Megna V, Al Ansari N, Marini A, Musio D . Unenhanced whole-body MRI versus PET-CT for the detection of prostate cancer metastases after primary treatment. Eur Rev Med Pharmacol Sci. 2016; 20(18):3770-3776. View

18.

Scher H, Morris M, Stadler W, Higano C, Basch E, Fizazi K . Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3. J Clin Oncol. 2016; 34(12):1402-18. PMC: 4872347. DOI: 10.1200/JCO.2015.64.2702. View

19.

Kesler M, Levine C, Hershkovitz D, Mishani E, Menachem Y, Lerman H . Ga-PSMA is a novel PET-CT tracer for imaging of hepatocellular carcinoma: A prospective pilot study. J Nucl Med. 2018; 60(2):185-191. DOI: 10.2967/jnumed.118.214833. View

20.

Ahmed H, El-Shater Bosaily A, Brown L, Gabe R, Kaplan R, Parmar M . Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study. Lancet. 2017; 389(10071):815-822. DOI: 10.1016/S0140-6736(16)32401-1. View